Loading
A phase 1/2 trial of Doxorubicin, Paclitaxel / nab-paclitaxel, Bevacizumab in sarcomas and ovarian cancer, run by GI Innovation, Inc., now recruiting.
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) is a phase 1/2 interventional study registered as NCT05824975 by GI Innovation, Inc., with 358 participants planned, started 2023-05-30 and due to reach its primary completion in 2025-11-12. Interventions recorded: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab. Conditions listed: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC). No results are recorded here; the registry entry is the source.
Shares Trastuzumab deruxtecan, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Eribulin, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Melanoma.